Singular Genomics Systems, Inc. [Rocket]

Overview

Singular Genomics Systems, Inc.

Add to portfolio

Recent News + Filings (All items)

Date Filed	Type	Description
08/17/2023	4	Ropp Sam (Chief Commercial Officer) has filed a Form 4 on Singular Genomics Systems, Inc.
08/15/2023	4	Kamdar Kim P. (Director) has filed a Form 4 on Singular Genomics Systems, Inc.
08/15/2023	144	Form 144 - Report of proposed sale of securities:
08/14/2023	SC 13G/A	Flynn James E reports a 7.4% stake in Singular Genomics Systems, Inc.
08/14/2023	144	Form 144 - Report of proposed sale of securities:
08/11/2023	144	Form 144 - Report of proposed sale of securities:
08/09/2023	10-Q	Quarterly Report for the period ended June 30, 2023

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-22	Dec-05-22	Dec-31-21	Dec-05-21	Dec-31-20	Dec-05-20	Dec-31-19
Revenues	0.8	0.8	0.0	0.0	0.0	21.2	10.5
Revenue growth				-100.0%	-100.0%
Cost of goods sold	0.8	0.8	0.0	0.0	0.0	42.5	21.0
Gross profit	0.0	0.0	0.0	0.0	0.0	-21.2	-10.5
Gross margin	1.4%	-3.1%				-100.0%	-100.0%
Selling, general and administrative	47.3	47.3	28.6	28.6	6.3	6.3
Research and development	46.2	46.2	32.7	32.7	21.2
General and administrative							2.3
EBIT	-93.5	-93.5	-61.3	-61.3	-27.5	-27.5	-12.8
EBIT margin	-11685.9%	-12220.5%				-129.6%	-121.8%
Pre-tax income	90.9	-90.9	98.8	-98.8	-27.9	-27.9	-12.3
Income taxes	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net income	90.9	-90.9	98.8	-98.8	-27.9	-27.9	-12.3
Net margin	11359.9%	-11879.6%				-131.5%	-117.6%

Diluted EPS	$1.28	($1.28)	$2.10	($2.10)	($2.64)	($2.64)	($1.43)
Shares outstanding (diluted)	71.1	71.1	47.0	47.0	10.6	10.6	8.6

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.